Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia von Arx
Observed names:
C. Von Arx,
C. von Arx,
CLAUDIA VON ARX,
Claudia Von Arx,
claudia von arx,
von Arx, Claudia
show all 6
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Regione Campania,
European Neuroendocrine Tumor Society,
Ovarian Cancer Action,
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori,
Imperial College London,
University of Naples Federico II
show all 8
ORCID:
0000-0001-6078-4271
Observed ORCID:
0000-0001-6078-4271
OpenAlex ID:
A5068786929
Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
2019
·
Monica Capozzi
, Chiara De Divitiis
, et al.
·
Cancer Management and Research
·
138
PDF
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
2022
·
Claudia von Arx
, Pietro De Placido
, et al.
·
Cancer Treatment Reviews
·
128
Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases
2015
·
Salvatore Tafuto
, Claudia von Arx
, et al.
·
International Journal of Surgery
·
75
Capecitabine Plus Gemcitabine in Thymic Epithelial Tumors: Final Analysis of a Phase II Trial
2014
·
Giovannella Palmieri
, Carlo Buonerba
, et al.
·
Future Oncology
·
51
Male Breast Cancer: From Molecular Genetics to Clinical Management
2022
·
Matilde Pensabene
, Claudia Von Arx
, et al.
·
Cancers
·
41
PDF
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results
2018
·
Sabino De Placido
, Mario Giuliano
, et al.
·
The Breast
·
37
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
2021
·
Irvin M. Modlin
, Mark Kidd
, et al.
·
Annals of Surgical Oncology
·
35
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors
2016
·
MONICA CAPOZZI
, CLAUDIA VON ARX
, et al.
·
Anticancer Research
·
33
Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes
2024
·
A. Calabrese
, C. von Arx
, et al.
·
Cancer Treatment Reviews
·
28
PDF
Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it
2015
·
Monica Capozzi
, Ieranò Caterina
, et al.
·
International Journal of Surgery
·
27
PDF
Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
2019
·
Claudia von Arx
, Monica Capozzi
, et al.
·
Journal of Clinical Medicine
·
26
PDF
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
2016
·
C. De Divitiis
, C. von Arx
, et al.
·
Journal of Translational Medicine
·
21
PDF
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020
·
Margaret Ottaviano
, Marcello Curvietto
, et al.
·
Journal for ImmunoTherapy of Cancer
·
20
PDF
Cancer genetic counselling for hereditary breast cancer in the era of precision oncology
2024
·
M. Pensabene
, A. Calabrese
, et al.
·
Cancer Treatment Reviews
·
18
PDF
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
2019
·
Salvatore Tafuto
, Claudia von Arx
, et al.
·
Journal of Clinical Medicine
·
17
PDF
Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions
2019
·
James R. Birtley
, Mohammad Alomary
, et al.
·
Nature Communications
·
15
PDF
Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors
2021
·
Antonella Lucia Marretta
, Giuseppe Di Lorenzo
, et al.
·
Pharmaceutics
·
12
PDF
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
2021
·
Michela Piezzo
, Roberta D’Aniello
, et al.
·
Pharmaceutics
·
11
PDF
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples
2017
·
ALESSANDRO OTTAIANO
, MONICA CAPOZZI
, et al.
·
Anticancer Research
·
10
PDF
Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
2020
·
Claudia von Arx
, Giuseppina Rea
, et al.
·
Cancers
·
9
PDF
Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.
2014
·
Carlo Buonerba
, Margaret Ottaviano
, et al.
·
Journal of Clinical Oncology
·
9
Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells
2024
·
Aurora Costa
, Iris Maria Forte
, et al.
·
Frontiers in Oncology
·
7
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
2024
·
C. von Arx
, G. Della Vittoria Scarpati
, et al.
·
ESMO Open
·
5
The Complex Management of the Breast Angiosarcoma: A Retrospective Study
2022
·
Lucia Cannella
, Francesco Perri
, et al.
·
Oncology
·
5
1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
2023
·
O. Clemente
, N. Starita
, et al.
·
Annals of Oncology
·
4
PDF
Show more works
View as search
Works count:
63
Citation count:
803
H-index:
15
I10-index:
19
Year
Topic
Type